Bostwick Marketing Mitomics' Prostate Cancer Dx in the US | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitochondrial DNA diagnostic test development firm Mitomics today announced a non-exclusive deal with Bostwick Laboratories for the marketing and distribution of the Prostate Core Mitomic Test in the US.

The urologic pathology laboratory will market the test under the name ProstaClear Mitomic Test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.